Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash from Operations for 10 consecutive years, with 99829000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 25.86% to 99829000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 466000000.0 through Dec 2025, down 12.56% year-over-year, with the annual reading at 466000000.0 for FY2025, 12.56% down from the prior year.
  • Cash from Operations for Q4 2025 was 99829000.0 at Ultragenyx Pharmaceutical, down from 91423000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 54344000.0 in Q4 2021, with the low at 190727000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 103708000.0, with a median of 93384000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 174.82% in 2021, then soared 43.16% in 2024.
  • Over 5 years, Cash from Operations stood at 54344000.0 in 2021, then crashed by 66.24% to 90342000.0 in 2022, then rose by 6.91% to 84098000.0 in 2023, then increased by 5.69% to 79315000.0 in 2024, then decreased by 25.86% to 99829000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 99829000.0, 91423000.0, and 108273000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.